CVS Health Corporation (NYSE:CVS) stands out as a compelling investment opportunity, particularly for those seeking robust blue-chip stocks priced under $100. Recent analyses by financial institutions like Truist underscore its potential, projecting continued growth and strong financial performance. The company's impressive first-quarter results for 2026, marked by significant revenue growth and an upward revision of its full-year earnings guidance, reflect a healthy operational trajectory and a promising outlook for investors.

Truist Boosts Price Target for CVS Health Amid Strong Performance

On a bright Monday, June 8, 2026, financial firm Truist elevated its price target for CVS Health Corporation (NYSE:CVS) to $108 from its previous $102, reaffirming its 'Buy' recommendation for the stock. This revised outlook is primarily based on the anticipated substantial earnings upside derived from ongoing margin improvements within CVS's government healthcare divisions, coupled with consistently strong trends in its commercial operations.

Analyst reports from Truist specifically highlighted that the first-quarter medical cost trends significantly surpassed consensus expectations, signaling a more favorable operational environment than anticipated. This positive development contributed to a robust financial showing for CVS Health. In the first quarter of 2026, the company reported total revenues soaring to $100.4 billion, marking a notable 6.2% increase compared to the same period in the prior year. Diluted earnings per share (GAAP) stood at $2.30, while adjusted earnings per share reached $2.57.

Buoyed by these encouraging results, CVS Health has revised its financial projections for the full fiscal year 2026. The company now forecasts its GAAP diluted EPS to fall within the range of $6.24 to $6.44, an increase from its earlier guidance of $5.94 to $6.14. These updated figures emphasize the company's confidence in its future performance and its strategic direction in delivering comprehensive health solutions.

CVS Health's strategic positioning within the healthcare solutions sector, combined with its solid financial performance and positive analyst sentiment, suggests a strong path forward. The company's ability to recover margins in government businesses and sustain momentum in commercial ventures paints a picture of resilience and growth. Investors might consider CVS Health not only for its current value but also for its potential to navigate evolving healthcare landscapes successfully. However, it is always wise for investors to conduct their own thorough due diligence and consider various market factors before making investment decisions.